Loading...
XNASWINT
Market cap73mUSD
Jan 08, Last price  
0.27USD
1D
-10.49%
1Q
-61.47%
Jan 2017
-100.00%
Name

Windtree Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:WINT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
49.00%
Rev. gr., 5y
-27.38%
Revenues
0k
1,209,000134,000004,600,00000582,000195,000388,0002,835,000987,0002,042,0001,485,0001,788,000198,0000000
Net income
-20m
L-48.25%
-46,203,000-58,904,000-46,333,000-40,005,000-39,106,000-30,240,000-19,175,000-20,965,000-37,315,000-45,215,000-44,058,000-55,170,000-39,490,000-18,446,000-20,533,000-29,862,000-30,280,000-67,636,000-39,208,000-20,291,000
CFO
-13m
L-30.92%
-33,342,000-57,668,000-39,826,000-29,395,000-31,752,000-27,415,000-24,270,000-22,698,000-32,884,000-40,454,000-41,169,000-33,504,000-33,589,000-21,045,000-15,781,000-24,663,000-25,315,000-23,664,000-19,452,000-13,437,000
Earnings
Apr 14, 2025

Profile

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
URL
https://windtreetx.com/
IPO date
Aug 09, 1995
Employees
20
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
17,539
22,950
Unusual Expense (Income)
NOPBT
(17,539)
(22,950)
NOPBT Margin
Operating Taxes
(1,367)
Tax Rate
NOPAT
(17,539)
(21,583)
Net income
(20,291)
-48.25%
(39,208)
-42.03%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,549
4,253
BB yield
-405.62%
-69.49%
Debt
Debt current
669
656
Long-term debt
17,758
3,652
Deferred revenue
Other long-term liabilities
3,800
18,800
Net debt
14,108
(2,018)
Cash flow
Cash from operating activities
(13,437)
(19,452)
CAPEX
(15)
(13)
Cash from investing activities
(15)
197
Cash from financing activities
11,595
3,079
FCF
(17,051)
(20,306)
Balance
Cash
4,319
6,172
Long term investments
154
Excess cash
4,319
6,326
Stockholders' equity
(844,817)
(824,532)
Invested Capital
868,838
855,624
ROIC
ROCE
EV
Common stock shares outstanding
220
40
Price
12.94
-91.54%
153.00
-89.41%
Market cap
2,847
-53.48%
6,120
-85.88%
EV
16,955
4,102
EBITDA
(17,457)
(22,417)
EV/EBITDA
Interest
50
53
Interest/NOPBT